Reve Technologies Stock Forecast, Price & News

+0.00 (+11.11 %)
(As of 06/18/2021 08:10 PM ET)
Today's Range
50-Day Range N/A
52-Week Range
Volume704.34 million shs
Average Volume182.21 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BSSP News and Ratings via Email

Sign-up to receive the latest news and ratings for Reve Technologies and its competitors with MarketBeat's FREE daily newsletter.

About Reve Technologies

Reve Technologies, Inc., a drug development company, provides advanced therapeutics for the treatment of cancer. It offers irreversible pepsin fraction (IPF), a therapeutic platform technology that is used to facilitate a range of applications. The company's solution is also used for the treatment of autoimmune diseases, such as cirrhosis and Hepatitis C. The company was founded in 2010 and is based in San Clemente, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.00 out of 5 stars

Medical Sector

2083rd out of 2,101 stocks

Biotechnology Industry

87th out of 89 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Reve Technologies (OTCMKTS:BSSP) Frequently Asked Questions

What stocks does MarketBeat like better than Reve Technologies?

Wall Street analysts have given Reve Technologies a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Reve Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Reve Technologies' key executives?

Reve Technologies' management team includes the following people:
  • Diana Zhabilov, Chairman & Pres

Who are some of Reve Technologies' key competitors?

What is Reve Technologies' stock symbol?

Reve Technologies trades on the OTCMKTS under the ticker symbol "BSSP."

How do I buy shares of Reve Technologies?

Shares of BSSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Reve Technologies' stock price today?

One share of BSSP stock can currently be purchased for approximately $0.00.

What is Reve Technologies' official website?

The official website for Reve Technologies is www.cantechpharma.com.

How can I contact Reve Technologies?

The company can be reached via phone at 714-907-1241.

This page was last updated on 6/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.